Miro Sciences LtdASX: MSX

Leading CRO Appointed for Phase 2 Crohn's Trial

· Issued by Miro Sciences Ltd via ASX

Filed with ASX · · 3 pages · English

On 6ix: 6ix.com/news/leading-cro-appointed-for-phase-2-crohns-trial-1

ASX:NSB +61 8 6268 2641 ir@neuroscientific.com Level 4, 216 St Georges Terrace, PERTH, WA, AUSTRALIA, 6000 ASX Announcement 01 October 2026 NeuroScienti?c Appoints Leading Clinical Research Organisation for Phase 2 Crohn's Disease Trial Southern Star Research appointed to support NSB's planned...

View Attachment

6ix is checking which company filed this.

Miro Sciences Ltd on 6ix

Earlier from Miro Sciences

Later from Miro Sciences

All Miro Sciences news releases